ICU MEDICAL INC annual report, FY2019

Full document

ICU Medical, Inc. — 2019 Form 10-K Summary

Reporting period: Fiscal year ended December 31, 2019. The filing is an annual report, not a standalone fourth-quarter filing; quarterly figures are unaudited. ICU Medical develops, manufactures and sells infusion therapy products, IV solutions, infusion systems, consumables and critical-care products. It acquired Pursuit Vascular in November 2019.

Financial performance and position

  • Revenue: $1.266 billion, down 9.6% from $1.400 billion in 2018. U.S. revenue was $923.3 million (73%); international revenue was $342.9 million (27%).
  • Product-line revenue: Infusion Consumables $477.6 million (down 1.1%); Infusion Systems $328.3 million (down 7.7%); IV Solutions $415.0 million (down 18.3%); Critical Care $45.3 million (down 15.3%).
  • Profit and margins: Gross profit was $471.9 million and gross margin 37.3%, versus $570.0 million and 40.7% in 2018. Operating income was $107.4 million, compared with $29.8 million; net income was $101.0 million, or $4.69 diluted EPS, versus $28.8 million, or $1.33 diluted EPS.
  • Cash flow and investment: Cash from operations was $101.9 million, down from $160.2 million. Purchases of property, plant and equipment were $97.3 million. Cash, cash equivalents and short-term investments totaled $292.6 million at year-end, down from $382.1 million.
  • Liquidity and debt: Working capital was $633.7 million. ICU had no borrowings and $150 million available under its revolving credit facility; it reported compliance with its financial covenants. Total assets were $1.692 billion and stockholders’ equity $1.377 billion.
  • Fourth quarter: Revenue was $315.5 million, gross profit $114.1 million and net income $20.6 million (diluted EPS $0.96). In Q4 2018, these were $340.4 million, $134.6 million and a $7.4 million net loss (diluted loss per share $0.36).

Changes versus 2018

  • Revenue fell mainly as temporary IV Solutions demand associated with competitors’ supply constraints normalized and customers returned to contract suppliers. Management also cited competitive conditions, exchange rates and lost non-core ambulatory and patient-controlled analgesia pump business.
  • Gross margin declined amid slower IV Solutions production, higher supply-chain costs and a $16.3 million inventory-optimization charge. Management said completed HIS integration generated cost improvements and efficiencies that partially offset the revenue decline.
  • Operating results benefited from lower SG&A and integration expenses, and a $47.4 million non-cash gain from revaluing the Pfizer/HIS earn-out liability. The earn-out period ended without performance targets being met, so no payment was due. These items make the year-over-year increase in earnings less indicative of underlying operating trends.

Outlook, risks and unusual items

  • Outlook: Management estimated 2020 capital expenditures of $85–$90 million, for manufacturing capacity, equipment placed with customers and IT. It expected existing cash and cash generated from operations to fund operations for the next 12 months. The filing provides no specific revenue or earnings guidance.
  • Pursuit acquisition: ICU paid approximately $75 million in cash for the business and recorded $17.3 million of contingent consideration; additional consideration of up to $50 million may be payable based on sales and gross-profit targets.
  • Integration and supply: 2019 restructuring, strategic transaction and integration expenses totaled $80.6 million, including a $22.1 million supply-chain restructuring charge and a $12.7 million non-cash write-off associated with Pfizer separation costs. Certain critical materials have sole-source suppliers; Clave components are made at one Salt Lake City facility. The filing also identified potential disruption from the coronavirus outbreak affecting suppliers and operations.
  • Market and regulatory exposure: Competition, hospital purchasing-group pricing pressure, reimbursement changes, product safety and quality requirements, data-security obligations, foreign exchange and international operations could affect results. IV Solutions production normalization and customer ordering patterns remain relevant to revenue.
  • Legal matters: ICU was named in pending U.S. antitrust litigation concerning saline solutions; it and Pfizer asserted reciprocal indemnification claims under the HIS purchase agreement. The Department of Justice’s separate antitrust investigation was closed in December 2018. A dispute with a product partner resulted in charges of $5.7 million in 2019 and $41.6 million in 2018.
  • Audit and controls: Deloitte issued an unqualified opinion on the financial statements and internal control over financial reporting. Revenue recognition estimates for distributor chargebacks were identified as a critical audit matter.

Most important facts for investors to verify

  • Whether IV Solutions revenue and gross margin stabilize as temporary competitor shortages and inventory adjustments unwind.
  • Whether Infusion Systems and Critical Care declines persist, and whether growth from Pursuit offsets weakness in established product lines.
  • Cash conversion and working-capital trends, particularly the increases in inventory and receivables and the decline in operating cash flow.
  • Actual 2020 capital spending versus the $85–$90 million estimate, and continued availability under the credit facility and covenant compliance.
  • The final Pursuit purchase-price allocation and any earn-out obligations, along with the remaining HIS integration and supply-chain costs.
  • Developments in saline antitrust litigation and indemnification claims, supplier continuity, and any material product-quality or regulatory events.